Immediate Impact

1 by Nobel laureates 3 from Science/Nature 57 standout
Sub-graph 1 of 22

Citing Papers

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial
2025 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
5 intermediate papers

Works of Eva Domingo‐Doménech being referenced

A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma
2020
A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data
2018

Author Peers

Author Last Decade Papers Cites
Eva Domingo‐Doménech 1051 1282 339 106 2.1k
Chiara Cattaneo 443 1221 296 99 2.1k
T. K. Chan 548 489 367 70 1.7k
Esa Jantunen 645 843 194 73 2.0k
Francesco Lauria 1071 997 1609 103 2.9k
Tsiporah B. Shore 321 898 369 149 2.3k
Marcus Hentrich 498 1010 195 97 2.2k
Gianpaolo Nadali 625 603 348 68 1.9k
Isidro Jarque 429 641 430 152 2.5k
Antonio Salar 1702 1175 792 151 2.8k
G.R. Morgenstern 215 906 296 50 2.6k

All Works

Loading papers...

Rankless by CCL
2026